Efficacy and Safety of Lobeglitazone Versus Sitagliptin

• ≥19 years old
• Waist line: male ≥ 90cm, female ≥ 85cm

• Applied to 1 or more categories listed below (NCEP-ATP III)

  1. SBP ≥ 130mmHg and/or DBP ≥ 85mmHg and/or taking drug for BP control
  2. HDL-C: male \< 40mg/dl, female \< 50mg/dl and/or taking drug for HDL-C increase
  3. TG ≥ 150mg/dl and/or taking drug for TG control

• At visit 1: Applied to 1 or more categories listed below

  1. Type 2 DM Patients who does not need stabilization period : 7% ≤ HbA1c ≤ 10%, if treated with Metformin ≥ 1000mg monotherapy at least 12 weeks prior to this study → Visit 3(Randomization)
  2. Type 2 DM Patients who need stabilization period : 7% ≤ HbA1c ≤ 10%, if not treated with Metformin ≥ 1000mg monotherapy at least 12 weeks prior to this study (Applied to 1 or more categories listed below) ① Drug Naïve ② Taking Metformin \< 1000mg monotherapy and/or Taking Metformin \< 12 weeks prior to this study ③ Taking OHA
• At visit 2(After 12 weeks of stabilization period): 7% ≤ HbA1c ≤ 10%
• Patients who signed informed consent form

Exclusion Criteria:

• Type 1 DM Patients or secondary DM
• Patients with ketoacidosis
• Patients with taking insulin > 7 days within 12 weeks
• Hypersensitive to biguanide and/or glitazone and/or DPP4-inhibitor
• Patients with taking corticosteroid > 7 days within 4 weeks
• Patients with lactic acidosis
• Patients with galactose intolerance and/or Lapp lactase deficiency and/or glucose-galactose malabsorption
• Patients with innutrition and/or starvation and/or weakness and/or pituitary insufficiency and/or addisons disease
• History of malignant tumor within 5 years
• History of drug or alcohol abuse within 12 weeks
• Patients with congestive heart failure(NYHA class III\~IV) or uncontrolled arrythmia within 6 months
• Patients with acute cardiovasvular disaese with 12 weeks

• Applied to 1 or more categories listed below

  1. AST and/or ALT ≥ 3*ULN
  2. Serum creatinine: male ≥ 1.5mg/dl, female ≥ 1.4mg/dl
  3. Hb \< 10.5g/dl
• Women with pregnant, breast-feeding
• Childbearing age who don't use adequate contraception
• Patients who have participated in other clinical trials
• Not eligible to participate for the study at the discretion of investigator